News Releases - DICE Therapeutics

Skip to main navigation

Careers Contact Search

About

Overview Leadership Board

Science

Pipeline

Overview IL-17 Integrin Programs

Investors

Overview News Releases Events and Presentations

Events Presentations

Corporate Governance

Governance Overview Committee Composition

Financial Information

SEC Filings Annual Reports and Proxy

Stock Information

Stock Quote & Chart

Shareholder Services

Investor FAQs Email Alerts RSS Feeds

Investors

News Releases

Year

Aug 11, 2022

DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights

Jul 21, 2022

DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

Jun 01, 2022

DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference

May 12, 2022

DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights

May 03, 2022

DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

Mar 28, 2022

DICE Therapeutics Expands Management Team and Board of Directors

Mar 21, 2022

DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Feb 10, 2022

DICE Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Quick Links

SEC Filings
RSS Feeds
Investor FAQs

Contact Us

Investors

investors@dicetx.com

Investor Email Alerts

Request Email Alerts

DICE Therapeutics ©

2022